MEDANTA
Global Health
Each stock's 10,000-path forecast, rendered as light.
Global Health (MEDANTA) Stock Analysis & Case Study
Is MEDANTA a good buy? The data-driven verdict.
Global Health (MEDANTA) trades at ₹1,288,on the numbers it tread carefully, a Downstox Snapshot Score of 35/100.
On the numbers, Global Health (MEDANTA) tread carefully, a Downstox Snapshot Score of 35/100, weighing expensive at 62.2× earnings, ROE of 15.2%, a 42% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
MEDANTA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is MEDANTA overvalued? MEDANTA P/E vs its sector
MEDANTA's P/E of 62.2× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.04% dividend yield is below the peer median of 1.65%.
MEDANTA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of MEDANTA history (-2%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MEDANTA 2027 | ₹792 | ₹1,188 | ₹1,769 | -6% |
| MEDANTA 2028 | ₹627 | ₹1,112 | ₹1,940 | -12% |
| MEDANTA 2029 | ₹516 | ₹1,043 | ₹2,076 | -18% |
| MEDANTA 2030 | ₹434 | ₹971 | ₹2,163 | -23% |
| MEDANTA 2031 | ₹368 | ₹915 | ₹2,254 | -28% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MEDANTA goes up, or doubles?
The bull case for MEDANTA
- A healthy 15.2% return on equity.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,076.
The bear case & risks
- A rich 62.2× P/E leaves a thin margin of safety if growth slows.
- A steep 8.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
- The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹516.
MEDANTA volatility & expected range, how bumpy is the ride?
Over the last 2.0 years MEDANTA compounded at -2%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹792–₹1,769, the honest backbone behind any single price target.
MEDANTA price forecast, the full 60-month probability fan
MEDANTA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MEDANTA hits common targets within the simulated horizon?
Full multi-horizon detail on the MEDANTA price target & forecast page.
MEDANTA Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. MEDANTA scores 4/9,mixed financial health.
MEDANTA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy MEDANTA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 29.9% | 3.3× |
| ZerodhaCHEAPEST | 29.9% | 3.3× |
| Dhan | 30.0% | 3.3× |
Compare every broker on the MEDANTA MTF page.
MEDANTA vs peers,sector comparison
About Global Health: sector, index & market-cap context
Global Health (MEDANTA) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹34,674 Cr. See more Nifty 100 stocks.
How the MEDANTA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Global Health's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MEDANTA analysis, FAQs
Is Global Health (MEDANTA) a good buy?
On the numbers, Global Health (MEDANTA) tread carefully, a Downstox Snapshot Score of 35/100, weighing expensive at 62.2× earnings, ROE of 15.2%, a 42% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MEDANTA overvalued or undervalued?
MEDANTA trades at 62.2× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the MEDANTA share price target for 2031?
MEDANTA's probability-weighted 2031 median target is ₹915, with an 80% range of ₹368–₹2,254 (10,000-path Monte-Carlo).
What is the probability MEDANTA doubles in 5 years?
The modelled probability of MEDANTA reaching ₹2,532 (2×) within 5 years is 7%.
What is the bull case for MEDANTA?
A healthy 15.2% return on equity.
What are the risks in MEDANTA?
A rich 62.2× P/E leaves a thin margin of safety if growth slows. A steep 8.8× price-to-book means most of the value is intangible/expectations, not assets on the books. The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.